A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

DynaNail Mini Fusion System for Subtalar Fusion Procedures Shows Positive Early Results

The initial clinical outcomes with the DynaNail Mini Fusion System for subtalar fusion procedures were reported today by MedShape. First used clinically under a limited market release in 2019, the DynaNail Mini has been implanted by over 50 orthopedic surgeons in over 50 hospitals across the United States.

The DynaNail Mini Fusion System features MedShape’s patented superelastic nickel-titanium (NiTiNOL) technology and is the first device designed for subtalar fusion that offers maintained active compression post-surgery.

Compression across the joint is important not only for ensuring the bones remain tightly apposed, but also in promoting the appropriate bone healing response.1 Screws currently represent the primary surgical treatment option in subtalar fusion procedures, but these devices are unable to hold compression following surgery when bone resorption and joint settling inherently occur. The DynaNail Mini features an internal NiTiNOL Compressive Element that allows for dynamic compression to be maintained post-surgery. The superelastic properties of NiTiNOL enable the DynaNail Mini to automatically adapt and respond to changes in the joint throughout the healing process while also allowing for immediate dynamization upon weight-bearing. Furthermore, the device includes two transverse locking screws to help provide additional joint stability and improved fixation.

Sam Adams, MD (Duke University) was one of the first surgeons to implant the DynaNail Mini and has performed numerous surgeries with the longest follow-up results now at 9 months. According to Dr. Adams:

“The DynaNail Mini with its internal NiTiNOL element is an unrivaled device for subtalar fusion. Its maintained post-operative compression and transverse locking screws give me the confidence that I can achieve successful outcomes where traditional compression screws might fail. To date, my Mini patients have all successfully fused with no complications. The device is truly a gamechanger!”

The DynaNail Mini has been used to address a number of different pathologies and indications including revisions of prior failed fusions, calcaneal fractures, and severe deformity. Most notably according to the literature, patients who have a prior ankle fusion have shown to be significantly more at risk for subtalar non-union.2  Another early adopter, Terrence Philbin, DO (Orthopedic Foot & Ankle), is seeing successful outcomes with the DynaNail Mini:

“Overall, I have been pleased with the results I have achieved with the DynaNail Mini to treat classically challenging indications,” said Dr. Philbin. “In particular, I have implanted the DynaNail Mini in two patients with prior ankle fusions. At 6 and 3 months post-surgery, both patients have shown successful bony union on CT and are doing well clinically. I look forward to expanding my indications for use with this innovative product.” 

The DynaNail Mini joins its predecessor, the DynaNail® TTC Fusion System, in MedShape’s growing NiTiNOL product portfolio that also includes the DynaClip® Bone Fixation System. Commercially available since 2013, the clinical power of the DynaNail to treat complex hindfoot pathologies in high-risk patient populations has been demonstrated in numerous peer-reviewed articles3,4 suggesting the potential clinical utility of the DynaNail Mini for other foot & ankle applications.

“We are very pleased with the market acceptance and clinical results observed so far for the DynaNail Mini,” said Kurt Jacobus, Ph.D. (MedShape, Inc. President & CEO). “Building off the momentum of the DynaNail TTC System, the Mini is poised to be another revolutionary device in joint fusion.”

The DynaNail Mini Fusion System is now available in full market release for subtalar fusion in a variety of diameter and length offerings.

Note: The DynaNail Mini will be featured at the upcoming American College of Foot & Ankle Surgeons Scientific Conference in Austin, Texas at the company’s booth #935. 


References

1Dupont KM, Shibuya N, Bariteau JT. Tibiotalocalcaneal Arthrodesis with Intramedullary Nails – Mechanobiological Background and Evolution of Compressive Technology. Global J of Orthopedics Research, 2019. 1(5): 1-8. 
2Zanolli DH, Nunley JA, Easley ME. Subtalar Fusion Rate in Patients With Previous Ipsilateral Ankle Arthrodesis. Foot & Ankle Int, 2015. 36(9): 1025-1028. 
3Steele JR, Easley ME, Nunley JA, Adams SB, et al. Comparison of Tibiotalocalcaneal Arthrodeses Using a Sustained Dynamic Compression Nail Versus Nondynamized Nails. Foot & Ankle Spec, 2019 (in press: doi: https://journals.sagepub.com/doi/10.1177/1938640019843332).
4Ford SE, Kwon JY, Ellington K. Tibiotalocalcaneal Arthrodesis Utilizing a Titanium Intramedullary Nail With an Internal Pseudoelastic Nitinol Compression Element: A Retrospective Case Series of 33 Patients. J Foot Ankle Surg, 2019. 58(2): 266-272.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy